Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lethagen

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Journal of Thrombosis and Haemostasis : JTH|April 15, 2011
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)A Tiede, U Friedrich, C Stenmo, et al.
Journal of Thrombosis and Haemostasis : JTH|February 3, 2015
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialP Chowdary, S Lethagen, U Friedrich, et al.
Journal of Thrombosis and Haemostasis : JTH|December 20, 2005
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter studyF Rodeghiero, G Castaman, A Tosetto, et al.
Journal of Thrombosis and Haemostasis : JTH|September 27, 2006
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter studyG Castaman, F Rodeghiero, A Tosetto, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 2011
A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand diseaseA Tosetto, F Rodeghiero, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 16, 2010
Functional characteristics of N8, a new recombinant FVIIIM L S Christiansen, K W Balling, E Persson, et al.
Thrombosis Research|July 24, 2010
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWDG Castaman, A Tosetto, A Cappelletti, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)A Tosetto, F Rodeghiero, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 21, 2016
European retrospective study of real-life haemophilia treatmentE Berntorp, G Dolan, C Hay, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWDJ Eikenboom, V Van Marion, H Putter, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Journal of Thrombosis and Haemostasis : JTH|April 15, 2011
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)A Tiede, U Friedrich, C Stenmo, et al.
Journal of Thrombosis and Haemostasis : JTH|February 3, 2015
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialP Chowdary, S Lethagen, U Friedrich, et al.
Journal of Thrombosis and Haemostasis : JTH|December 20, 2005
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter studyF Rodeghiero, G Castaman, A Tosetto, et al.
Journal of Thrombosis and Haemostasis : JTH|September 27, 2006
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter studyG Castaman, F Rodeghiero, A Tosetto, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 2011
A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand diseaseA Tosetto, F Rodeghiero, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 16, 2010
Functional characteristics of N8, a new recombinant FVIIIM L S Christiansen, K W Balling, E Persson, et al.
Thrombosis Research|July 24, 2010
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWDG Castaman, A Tosetto, A Cappelletti, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)A Tosetto, F Rodeghiero, G Castaman, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 21, 2016
European retrospective study of real-life haemophilia treatmentE Berntorp, G Dolan, C Hay, et al.
Journal of Thrombosis and Haemostasis : JTH|April 26, 2006
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWDJ Eikenboom, V Van Marion, H Putter, et al.
Pageof 10